More generally, our results in a zebrafish model of Lxrα deletion and cell type-limited over-expression are important because postprandial dyslipidemia is not amenable to most currently available lipid-lowering therapies (Nordestgaard and Varbo, 2014). This evidence concerns the gene NR1H3 and metabolic syndrome.